Skip to main content
S&P 5007,634.83+1.10%DOW51,801.88+0.66%NASDAQ26,402.67+1.63%BTC$76,810.00+1.53%ETH$2,471.34+3.45%GOLD$4,401.50+0.32%OIL$102.01-0.41%
Smart Investors Daily
AR

NASDAQ · ARTL

Artelo Biosciences, Inc.

Healthcare · Biotechnology

$3.75

Up+$0.13 (+3.47%)

Updated Sep 17, 2026, 5:10 PM

SID Score

6.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.75M
P/E ratio
-0.1
Dividend yield
0.00%
52-week range
$0.66 – $19.91
Volume
277.96K
Avg. volume
491.32K

Price performance

ARTL price history

1M range · 0 trading sessions · Daily adjusted prices

ARTL does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest ARTL news

The latest Smart Investors Daily articles mentioning ARTL.

Stock researchCompany · Overview

ARTL research

Overview

Company profile and research snapshot.

Company profile

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
ARTL recent ratings
DateFirmRatingTarget
Nov 19, 2025Maxim GroupHold—
Sep 8, 2025D. Boral CapitalHold—
Aug 26, 2025D. Boral CapitalBuy—
Aug 18, 2025D. Boral CapitalBuy—
Aug 6, 2025D. Boral CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 8, 2026

Artelo Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference

SOLANA BEACH, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced that Gregory D. Gorgas, CEO of Artelo Biosciences, will be participating in the H.C. Wainwright 28th Annual Global Investment Conference being held September 14-16, 2026

Yahoo · Aug 27, 2026

Artelo Biosciences Announces Reverse Stock Split

Shares Expected to Begin Trading on a Split-Adjusted Basis on August 31, 2026SOLANA BEACH, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today announced a 1-for-9 reverse stock split (“Reverse Split”) of the Company’s common stock (“Common Stock

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By